Anocarriers for Hyperproliferative Skin Illnesses. Cancers 2021, 13, 5619. https:// doi.org/10.3390/cancers13225619 AcademicAnocarriers for Hyperproliferative Skin

Anocarriers for Hyperproliferative Skin Illnesses. Cancers 2021, 13, 5619. https:// doi.org/10.3390/cancers13225619 Academic
Anocarriers for Hyperproliferative Skin Diseases. Cancers 2021, 13, 5619. https:// doi.org/10.3390/cancers13225619 Academic Editors: Maciej Wnuk and Anna Lewinska Received: 6 October 2021 Accepted: five November 2021 Published: 10 NovemberCEB–Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal Faculty of Pharmaceutical Sciences, S Paulo State University (UNESP), Campus of Araraquara, Rodovia PHA-543613 In Vivo Araraquara Ja Araraquara 14800-903, SP, Brazil; [email protected] (A.L.R.d.S.); [email protected] (F.K.d.S.); [email protected] (M.P.D.G.); [email protected] (M.C.) Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Meals Sciences, University of Barcelona, 08007 Barcelona, Spain; [email protected] (E.S.-L.); [email protected] (A.C.) Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08007 Barcelona, Spain Institute of Human Genetics, Polish Academy of Sciences, Strzeszynska 32, 60-479 Poznan, Poland; [email protected] Department of Hypertension Angiology and Internal (Z)-Semaxanib Technical Information Medicine, Poznan University of Medical Sciences, 61-701 Poznan, Poland; [email protected] Department of Environmental Medicine, Poznan University of Health-related Sciences, 61-701 Poznan, Poland Department of Gastroenterology, Dietetics and Internal Ailments, H. Swiecicki University Hospital, Poznan University of Health-related Sciences, 60-355 Poznan, Poland Correspondence: [email protected] (E.B.S.); [email protected] (J.K.)Easy Summary: Distinctive drugs, including antiproliferative and corticosteroids normally, are recommended for the therapy of hyperproliferative skin diseases (HSD). The effectiveness of numerous of these drugs is limited as a result of their low solubility in water and low penetration inside the skin. The loading of these drugs in lipid nanocarriers, for instance lipid nanoparticles and liposomes, has been regarded as a profitable resolution to improve the drug bioavailability via the skin, to handle their release kinetics and hence lower the risk of potential negative effects. Within this function, we go over the usage of lipid nanocarriers loading drugs against HSD. Abstract: Hyperproliferative skin ailments (HSD) are a group of ailments that contain cancers, precancerous lesions and illnesses of unknown etiology that present diverse skin manifestations when it comes to the degree and distribution on the injuries. Anti-proliferative agents used to treat these diseases are so diverse, such as 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids normally. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed using the major objective to boost the effectiveness of topical therapy and cut down side effects. This manuscript aims to describe the advantages of working with lipid nanoparticles and liposomes that can be employed to load diversity of chemically unique drugs for the therapy of HSD. Keywords and phrases: lipid nanoparticles; liposomes; hyperproliferative skin ailments; antiproliferative drugs; skin cancerPublisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.Copyright: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This short article is an open access write-up distributed under the t.